IP Library Granted Patent US 8,754,222
Granted Patent B2
US 8,754,222 · App. 13/678,840 · Granted Jun 17, 2014

Process for preparing modulators of cystic fibrosis transmembrane conductance regulator

Inventors: Narendra Bhalchandra Ambhaikar (Hyderabad, IN); Robert Hughes (San Diego, CA); Dennis James Hurley (San Marcos, CA); Elaine Chungmin Lee (Cambridge, MA); Benjamin Littler (Carlsbad, CA); Mehdi Numa (San Diego, CA); Stefanie Roeper (Medford, MA); Urvi Sheth (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,754,222
App. No.
13/678,840
Granted
Jun 17, 2014
Kind
B2
Abstract

The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.

Claims (18)

1. A process for producing the hydrochloride salt of Compound 1 having solid Form A-HCl:

comprising:

(a) reacting Compound 2 with the hydrochloride salt of Formula 3 (3-HCl) in the presence of a coupling agent selected from the group consisting of 2-chloro-1,3-dimethyl-2-imidazolium tetrafluoroborate, HBTU, HCTU, 2-chloro-4,6-dimethoxy-1,3,5-triazine, HATU, HOBT/EDC, and propane phosphonic anhydride:

 and

(b) treating a mixtures of the product of step (a) with HCl.

2. The process of claim 1 , wherein step (a) is performed in the presence of a base such as K 2 CO 3 , Et 3 N,N-methylmorpholine (NMM), pyridine or diisopropylethyl amine (DIEA).

3. The process of claim 2 , wherein step (a) is performed in the presence of pyridine or DIEA.

4. The process of claim 3 , wherein step (a) is performed in the presence of pyridine.

5. The process of claim 1 , wherein step (a) is performed in the presence of a polar aprotic solvent.

6. The process of claim 5 , wherein the polar aprotic solvent is selected from the group consisting of ethyl acetate, isopropyl acetate, tetrahydrofuran, methylethyl ketone, N-Methyl-2-pyrrolidone, acetonitrile, N,N-dimethyl formamide, or 2-methyltetrahydrofuran.

7. The process of claim 1 , wherein the coupling of Compound 2 and 3-HCl is performed in the presence of 2-methyltetrahydrofuran.

8. The process of claim 1 , wherein step (a) is performed at a reaction temperature that is maintained between 10° C. and 80° C.

9. The process of claim 8 , wherein step (a) is performed at a reaction temperature that is maintained between 15° C. and 70° C.

10. The process of claim 1 , wherein the time of step (a) is from about 1.5 hours to about 72 hours.

11. The process of claim 1 , wherein HCl gas is used in step (b).

12. The process of claim 11 , wherein HCl gas is bubbled into a mixture comprising the product of step (a) and a polar aprotic solvent.

13. The process of claim 12 , wherein the polar aprotic solvent is 2-Methyltetrahydrofuran.

14. The process of claim 12 , wherein HCl gas is bubbled into the mixture comprising the product of step (a) and a polar aprotic solvent for a period of from about 0.5 hours to about 5 hours.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 17, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037845/0106 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2013
From: AMBHAIKAR, NARENDRA BHALCHANDRA; HUGHES, ROBERT; HURLEY, DENNIS JAMES; LEE, ELAINE CHUNGMIN; LITTLER, BENJAMIN; NUMA, MEHDI; ROEPER, STEFANIE; SHETH, URVI
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 030335/0377 →
Continuity (3)
Division 12909750 · Oct 21, 2010
Provisional Application 61254634 · Oct 23, 2009
Related Publication 20130072687A1 · Mar 21, 2013